US Patent Issued to Unity Biotechnology, Mayo Foundation for Medical Education and Research, Buck Institute for Research on Aging on April 29 for "Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor" (California, Minnesota Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,285,427, issued on April 29, was assigned to Unity Biotechnology Inc. (South San Francisco, Calif.), Mayo Foundation for Medical Education and Research (Rochester, Minn.) and Buck Institute for Research on Aging (Novato, Calif.).

"Treatment of a senescence-associated ocular disease or disorder using a Bcl-xL selective inhibitor" was invented by Remi-Martin Laberge (South San Francisco, Calif.), Judith Campisi (Berkeley, Calif.), Marco Demaria (San Francisco), Bennett G. Childs (Rochester, Minn.), Jan M. A. Van Deursen (Rochester, Minn.), Nathaniel David (South San Francisco, Calif.) and Alain Philippe Vasserot (South San Francisco, Calif.).

According to the abstract* released by the U...